A Phase 2 interventional study of LY3871801 and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 54 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
2,888 studies on the registry are indexed under Arthritis, Rheumatoid; 390 are open to participants now.
This study's enrollment of 164 is above the median of 94 across 1,984 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Have moderately-to-severely active RA at screening and baseline, defined by the presence of
Exclusion Criteria:
Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to
major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to
Participants will receive LY3871801 administered orally.
Drug: LY3871801
Participants will receive placebo.
Drug: Placebo
Participants will receive LY3871801 administered orally.
Drug: LY3871801
Participants will receive LY3871801 administered orally.
Drug: LY3871801
Participants will receive LY3871801 administered orally.
Drug: LY3871801
Participants will receive placebo.
Drug: Placebo
Administered orally
Administered orally
Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)
Time frame: Baseline, Week 12
Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50
Time frame: Baseline to Week 12
Phase 2a: Percentage of Participants Achieving ACR20/50/70
Time frame: Baseline to Week 12
Phase 2b: Change from Baseline in DAS28-hsCRP
Time frame: Baseline, Week 12
Phase 2b: Percentage of Participants Achieving ACR20/70
Time frame: Week 12
Change from Baseline in Simplified Disease Activity Index (SDAI)
Time frame: Baseline, Week 12
Change from Baseline in Clinical Disease Activity Index (CDAI)
Time frame: Baseline, Week 12
Change from Baseline in ACR Core Set Values 68 Tender Joint Counts
Time frame: Baseline, Week 12
Change from Baseline in ACR Core Set Values 66 Swollen Joint Counts
Time frame: Baseline, Week 12
Change from Baseline in ACR Core Set Values Physician's Global Assessment of Disease Activity (PhGADA) Visual Analog Scale (VAS)
Time frame: Baseline, Week 12
Change from Baseline in ACR Core Set Values Patient's Global Assessment of Disease Activity (PaGADA) VAS
Time frame: Baseline, Week 12
Change from Baseline for Participant's Assessment of Arthritis Pain (VAS)
Time frame: Baseline, Week 12
Change from Baseline for Participant's Assessment of Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time frame: Baseline, Week 12
Change from Baseline the Duration and Severity of Morning Joint Stiffness
Time frame: Baseline, Week 12
Change from Baseline for Short Form-36 (SF-36) Physical Component Summary Score
Time frame: Baseline, Week 12
Change from Baseline for SF-36 Mental Component Summary Score
Time frame: Baseline, Week 12
Pharmacokinetics (PK) Trough Plasma Concentrations of LY3871801
Time frame: Baseline through Week 20
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company